Navigation Links
InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009

MADISON HEIGHTS, Mich., May 5 /PRNewswire-FirstCall/ -- InfuSystem Holdings, Inc. (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced financial results and provided a business update for the first quarter ended March 31, 2009.

Mr. Steve Watkins, chief executive officer, commented, "We achieved $9.2 million of revenue during the first quarter of 2009, despite a nationwide shortage of Leucovorin, a compound frequently used in association with ambulatory pump chemotherapy, which has since been resolved. At the same time, we increased gross margins by 560 basis points and continue to gain operating leverage as we held our costs in line. As a result, we generated $2.9 million of adjusted EBITDA, a 45% increase compared to the first quarter of 2008. This contributed to the Company's continued strong operating cash flow and ample cash reserves, allowing us to improve the balance sheet by aggressively paying down debt. Shortly following the first quarter, we made a $5.3 million payment on our term loan, resulting in the Company having lowered its term loan balance by over $6.1 million year-to-date."

Mr. Watkins concluded, "We remain encouraged by the near- and long-term outlook for the ambulatory infusion services market. Drug companies are incorporating continuous infusion as part of their drug treatment regimens and promoting these to oncologists. The American Cancer Society estimated that there were about 148,810 new cases of colorectal cancer in 2008 in the United States. Moreover, the combined benefits to the patient, physician and insurance provider support the expanded use of ambulatory infusion pumps to administer chemotherapy beyond stage III colorectal cancer, including esophageal, head and neck, gastric and other cancers. In order to best capitalize on this market opportunity, we continue to enhance our sales organization, including the recent addition of Bryan Russo as chief commercial officer. We look forward to his contributions as we focus on accelerating and deepening our penetration of oncology practices nationwide. Looking ahead, we anticipate continued organic revenue growth, greater operational efficiencies, and continued strong cash flow to allow for paying down additional debt in 2009."

Financial Results

Revenue for the first quarter ended March, 31 2009 was $9.2 million, an 8.2% improvement compared to $8.5 million for the same period in 2008. The increase in revenue was primarily due to obtaining business at new customer facilities, increased reimbursement, as well as improved collection efficiencies. Operating income for the first quarter of 2009 was $1.3 million versus operating income of $521,000 for the same period in 2008. The increase in operating income for the first quarter of 2009 was due, in part, to increased sales and lower product and supply costs, which were partially offset by an increase in selling and marketing expenses.

The net loss for the first quarter of 2009 was ($2.5 million), or $(0.14) per diluted share, compared to net income of $4.8 million or $0.29 per diluted share, for the same period in 2008. The net income for the first quarter of 2009 included a ($2.6 million) loss on derivative financial instruments, which was predominantly attributable to the increase in the publicly traded value of the Company's warrants during the quarter, compared to a $5.2 million gain for the first quarter of 2008.

Adjusted EBITDA for the first quarter ended March 31, 2009 was $2.9 million, compared to $2.0 million for the same period in 2008. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, and excludes gain (loss) on derivative financial instruments and stock-based compensation. Adjusted EBITDA is not a measure of performance calculated in accordance with generally accepted accounting principles in the United States ("GAAP"). The Company believes the presentation of Adjusted EBITDA is a relevant and useful measure to assist a reader's ability to understand the Company's operating performance. The Company's management likewise utilizes Adjusted EBITDA as a means to measure its operating performance. The table below reconciles Adjusted EBITDA, a non-GAAP measure, to net income.

                                                 Three Months Ended
     Reconciliation from Net                          March 31
      Income to Adjusted EBITDA:

                                               2009             2008
     Net Income                             $(2,507)          $4,797
       Interest expense                         989              958
       Interest income                           (3)              (3)
       Income tax expense                       140                -
       Depreciation -- Pumps                    840              963
       Depreciation -- Other                     32               41
       Amortization                             457              457
     EBITDA                                    $(52)          $7,213
       Loss (gain) on derivatives             2,642           (5,231)
       Stock based compensation                 278                -
     Adj. EBITDA                             $2,868           $1,982

About InfuSystem Holdings, Inc.

InfuSystem is the leading provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. InfuSystem's pumps are primarily used for colorectal cancer, but they have been approved for other forms of cancer, thereby greatly enhancing the market opportunity for InfuSystem.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.

                          INFUSYSTEM HOLDINGS, INC.
                         CONSOLIDATED BALANCE SHEETS

                                                 March 31, December 31,
    (in thousands, except share data)              2009         2008
     Current Assets:
      Cash and cash equivalents                    $11,358      $11,513
      Accounts receivable, less allowance
       for doubtful accounts of $1,680 and
       $1,552 at  March 31, 2009 and
       December 31, 2008, respectively;
       March 31, 2009 and December 31, 2008
       include $121 and $72 due from I-Flow,
       respectively                                  4,636        4,168
      Inventory supplies                               432          391
      Prepaid expenses and other current assets      1,026          676
        Total Current Assets                        17,452       16,748
     Property & equipment, net                      10,833       10,878
     Deferred debt issuance costs, net               1,133        1,276
     Goodwill                                       56,580       56,580
     Intangible assets, net                         30,282       30,738
      Total Assets                                $116,280     $116,220
     Current Liabilities:
      Accounts payable                              $1,368       $1,012
      Deferred income taxes                             55           55
      Other current liabilities                      1,069          939
      Derivative liabilities                         5,235        2,592
      Current portion of long-term debt;
       both March 31, 2009 and December 31,
       2008 include $8,564 payable to I-Flow         8,645        8,644
        Total Current Liabilities                   16,372       13,242
     Long-term debt, net of current portion;
      March 31, 2009 and December 31, 2008
      include $20,868 and $21,685 payable
      to I-Flow, respectively                       21,185       22,025
     Deferred income taxes                             880          880
        Total Liabilities                          $38,437      $36,147
      Stockholders' Equity
      Preferred stock, $.0001 par value:
       authorized 1,000,000                              -            -
       shares; none issued
      Common stock, $.0001 par value;
       authorized 200,000,000
       shares; issued 18,537,671 and
       18,512,671, respectively;
       outstanding 18,537,671
       and 17,278,626, respectively                      2            2
      Additional paid-in capital                    81,069       80,792
      Retained deficit                              (3,228)        (721)
      Total Stockholders' Equity                    77,843       80,073
        Total Liabilities and Stockholders'
         Equity                                    $116,280    $116,220

                       INFUSYSTEM HOLDINGS, INC.

                                            Three Months Ended March 31
     (in thousands, except per share data)       2009        2008

     Net revenues                               $9,227      $8,530

     Operating expenses:
     Cost of Revenues -- Product
      and supply costs                           1,270       1,465
     Cost of Revenues -- Pump depreciation         840         963
     Provision for doubtful accounts               969         861
     Amortization of intangibles                   457         457
     Selling and marketing                       1,320       1,077
     General and administrative                  3,110       3,186
     Total Operating Expenses                    7,966       8,009
      Operating income                           1,261         521
     Other (loss) income:
     (Loss) gain on derivatives                 (2,642)      5,231
     Interest income                                 3           3
     Interest expense                             (989)       (958)
     Total other (loss) income                  (3,628)      4,276

     (Loss) income before income taxes          (2,367)      4,797
     Income tax expense                           (140)          -
     Net (loss) income                          (2,507)      4,797

     Net (loss) income per share:
      Basic & Diluted                            (0.14)       0.29
     Weighted average shares outstanding:
      Basic & Diluted                       18,531,838  16,824,295

                       INFUSYSTEM HOLDINGS, INC.

                                       Three Months Ended March 31
     (in thousands)                           2009      2008

     Net (Loss) Income                      (2,507)    4,797
    Adjustments to reconcile net
     (loss) income to net cash
     provided by operating activities:
     Loss (gain) on derivative liabilities   2,642    (5,231)
     Provision for doubtful accounts           969       861
     Depreciation                              872     1,004
     Amortization of intangible assets         457       457
     Amortization of deferred debt
      issuance costs                           143       180
     Loss on disposal of assets                109       225
     Stock-based compensation                  278         -
    Changes in current assets and
     (Increase) decrease in accounts
      receivable, net of provision          (1,437)      187
     (Increase) decrease in prepaid
      expenses and other current assets       (391)      803
     Increase in accounts payable and
      other current liabilities                134       140
      ACTIVITIES                             1,269     3,423

     Payment of deferred acquisition
      costs                                      -       (97)
     Capital expenditures                     (586)     (447)
     Proceeds from sale of property              1         -
      ACTIVITIES                              (585)     (544)

     Principal payments on term loan          (818)     (409)
     Principal payments on capital
      lease obligation                         (21)        -
      ACTIVITIES                              (839)     (409)

     Net change in cash and cash
      equivalents                             (155)    2,470
     Cash and cash equivalents,
      beginning of period                   11,513     3,960
     Cash and cash equivalents, end of
      period                                11,358     6,430

SOURCE InfuSystem Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InfuSystem Appoints Bryan Russo as Chief Commercial Officer
2. InfuSystem Pays Down Term Loan by $6.1 Million Year-to-Date
3. InfuSystem Holdings Reports 12.9% Revenue Increase and $3.3 Million of Adjusted EBITDA for the Fourth Quarter of 2008
4. InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results
5. InfuSystem Holdings Appoints Two New Board Members
6. Duane Reade Holdings, Inc. Reports First Quarter 2009 Results
7. HMS Holdings Corp. Announces First Quarter 2009 Financial Results
8. China Pharma Holdings, Inc. Retains Global Investor Communications Team
9. China Pharma Holdings, Inc. Appoints Chief Financial Officer and Board Member
10. JAG Media Holdings, Inc. Announces Update of the Status of its Proposed Acquisition of CardioGenics Inc.
11. Innophos Holdings, Inc. Schedules Call to Discuss First Quarter 2009 Results
Post Your Comments:
(Date:4/28/2017)... ... ... much more than energy – it also has mental and physical benefits. According to the ... which can increase the risk of having a car accident. , This week is ... help you sleep better and feel better:, , Turn off all ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... , ... April 28, 2017 , ... People are starting ... people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa wore ... Associates of Greater Boston, in a NALA North American Speaker Series (NASS) ...
(Date:4/28/2017)... ... 28, 2017 , ... Intellitec Solutions announced the publication of ... Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software package. With ... care, Brooke Grove now has the capability to achieve its goal for a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Christie Medical Holdings, Inc. , with its ... B. Braun Medical Inc. , a leader in infusion therapy and pain management. ... as 90 percent of hospital patients receiving a peripheral IV catheter as part of ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, Inc. ... on providing the Urology, Uro/Gyn and Gynecology markets ... Ash Keswani has joined the Company as Senior ... newly created position, Mr. Keswani will report directly ... "Our organization is delighted that Ash ...
(Date:4/20/2017)... MARLBOROUGH, Mass. , April 20, 2017 /PRNewswire/ ... company developing innovative therapeutics that address significant unmet ... new data from the Company,s consumer product development ... technology, at the Society for Investigative Dermatology (SID) ... is to advance and promote the sciences relevant ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: